These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8138891)

  • 1. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.
    Relling MV; Evans RR; Groom S; Crom WR; Pratt CB
    J Pharmacokinet Biopharm; 1993 Dec; 21(6):639-51. PubMed ID: 8138891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. IV: Pharmacokinetics and toxicity of flavone acetic acid and its metabolites.
    Stratford MR; Rustin GJ; Dennis MF; Watfa RR; Howells N; O'Reilly SM
    Br J Cancer; 1993 Jun; 67(6):1351-5. PubMed ID: 8512820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flavone acetic acid distribution in human malignant tumors.
    Damia G; Freschi A; Sorio R; Braida A; Caruso G; Quaia M; Monfardini S; D'Incalci M
    Cancer Chemother Pharmacol; 1990; 26(1):67-70. PubMed ID: 2322990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
    McKeage MJ; Kestell P; Denny WA; Baguley BC
    Cancer Chemother Pharmacol; 1991; 28(6):409-13. PubMed ID: 1934244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid.
    Olver IN; Webster LK; Bishop JF; Stokes KH
    Cancer Chemother Pharmacol; 1992; 29(5):354-60. PubMed ID: 1551173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients?
    Cassidy J; Kerr DJ; Setanoians A; Zaharko DS; Kaye SB
    Cancer Chemother Pharmacol; 1989; 23(6):397-400. PubMed ID: 2713962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.
    Chabot GG; Bissery MC; Corbett TH; Rutkowski K; Baker LH
    Cancer Chemother Pharmacol; 1989; 24(1):15-22. PubMed ID: 2597279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-dependent pharmacokinetics of flavone acetic acid in mice.
    Damia G; Zanette ML; Rossi C; Mandelli R; Ferrari A; D'Incalci M
    Cancer Chemother Pharmacol; 1988; 22(1):47-50. PubMed ID: 3396145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavone acetic acid pharmacokinetics in nude mice.
    Damia G; Garofalo A; Rossi C; Giavazzi R; D'Incalci M
    Anticancer Res; 1990; 10(2A):437-9. PubMed ID: 2346316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouse.
    Chabot GG; Branellec D; Sassi A; Armand JP; Gouyette A; Chouaib S
    Eur J Cancer; 1993; 29A(5):729-33. PubMed ID: 8471332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavone acetic acid and plasma protein binding.
    Brodfuehrer J; Valeriote F; Chan K; Heilbrun L; Corbett T
    Cancer Chemother Pharmacol; 1990; 27(1):27-32. PubMed ID: 2245490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.
    Maughan TS; Ward R; Dennis I; Honess DJ; Workman P; Bleehen NM
    Br J Cancer; 1992 Sep; 66(3):579-82. PubMed ID: 1520597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide.
    Giacomini KM; Swezey SE; Turner-Tamiyasu K; Blaschke TF
    J Pharmacokinet Biopharm; 1982 Feb; 10(1):1-14. PubMed ID: 7069575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status.
    Bibby MC; Phillips RM; Double JA; Pratesi G
    Br J Cancer; 1991 Jan; 63(1):57-62. PubMed ID: 1989665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic modelling of total and unbound plasma carboplatin--a population study in 75 children.
    Urien S; Doz F; Namouni F; Bastian G
    Int J Clin Pharmacol Ther; 2002 Jun; 40(6):270-8. PubMed ID: 12078941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of flavone acetic acid (NSC 347512, LM975) in patients with pediatric malignant solid tumors.
    Pratt CB; Relling MV; Meyer WH; Douglass EC; Kellie SJ; Avery L
    Am J Clin Oncol; 1991 Dec; 14(6):483-6. PubMed ID: 1957836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic-pharmacodynamic model of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid in cancer patients.
    Li J; Jameson MB; Baguley BC; Pili R; Baker SD
    Clin Cancer Res; 2008 Apr; 14(7):2102-10. PubMed ID: 18381951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
    Sonnichsen DS; Hurwitz CA; Pratt CB; Shuster JJ; Relling MV
    J Clin Oncol; 1994 Mar; 12(3):532-8. PubMed ID: 7907130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
    Webster LK; Ellis AG; Kestell P; Rewcastle GW
    Drug Metab Dispos; 1995 Mar; 23(3):363-8. PubMed ID: 7628302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization.
    de Forni M; Chabot GG; Armand JP; Gouyette A; Klink-Alak M; Recondo G
    Cancer Chemother Pharmacol; 1995; 35(3):219-24. PubMed ID: 7805180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.